Benjamin Eades

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, Jennifer To, Tanya M. Spektor et al. · Clinical Cancer Research · 2020 · 36 citations

Medicine, Pharmacology, Pharmacotherapy +13

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

James R. Berenson, Ori Yellin, Chien‐Shing Chen et al. · British Journal of Haematology · 2011 · 31 citations

Medicine, Pharmacology, Pharmacotherapy +17

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen

James R. Berenson, Ori Yellin, Donald Woytowitz et al. · European Journal Of Haematology · 2009 · 26 citations

Medicine, Hematology, Pharmacotherapy +15

A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma

Gabriel N. Waterman, Ori Yellin, Regina A. Swift et al. · Annals of Hematology · 2010 · 18 citations

Medicine, Oncology, Pharmacology +16

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

Ariana Berenson, Suzie Vardanyan, Michael David et al. · Annals of Hematology · 2016 · 17 citations

Medicine, Hematology, Pharmacotherapy +12